Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.

Abstract:

Background:The diagnostic work-up of pediatric irritable bowel syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) commonly includes invasive tests for discrimination from inflammatory bowel disease (IBD). As this carries a high burden on patients, an ongoing need exists for development of noninvasive diagnostic biomarkers for IBS and FAP-NOS. Several studies have shown microbiota alterations in IBS/FAP, which are considered to be reflected by fecal volatile organic compounds (VOCs). The object of the study was to evaluate whether pediatric IBS/FAP-NOS could be discriminated from IBD and healthy controls by fecal VOC analysis. Methods:IBS/FAP-NOS was diagnosed according to the ROME IV criteria, and de novo IBD patients and healthy controls (HCs) aged 4 to 17 years were matched on age and sex. Fecal VOCs were analyzed by means of field asymmetric ion mobility spectrometry. Results:Fecal VOCs of 15 IBS/FAP-NOS, 30 IBD (15 ulcerative colitis, 15 Crohn's disease) patients and 30 HCs were analyzed and compared. Differentiation between IBS/FAP-NOS and IBD was feasible with high accuracy (area under the curve [AUC], 0.94; 95% confidence interval [CI], 0.88-1; P < 0.00001). IBS/FAP-NOS profiles could not be differentiated from HCs (AUC, 0.59; 95% CI, 0.41-0.77; P = 0.167), whereas IBD profiles could with high accuracy (AUC, 0.96; 95% CI, 0.93-1; P < 0.00001). Conclusion:Pediatric IBS/FAP-NOS could be differentiated from IBD by fecal VOC analysis with high accuracy, but not from healthy controls. The latter finding limits the potential of fecal VOCs to serve as a diagnostic biomarker for IBS/FAP-NOS. However, VOC could possibly serve as additional noninvasive biomarker to differentiate IBS/FAP-NOS from IBD. 10.1093/ibd/izy151_video1izy151.video15786446046001.

journal_name

Inflamm Bowel Dis

authors

Bosch S,van Gaal N,Zuurbier RP,Covington JA,Wicaksono AN,Biezeveld MH,Benninga MA,Mulder CJ,de Boer NKH,de Meij TGJ

doi

10.1093/ibd/izy151

subject

Has Abstract

pub_date

2018-10-12 00:00:00

pages

2468-2475

issue

11

eissn

1078-0998

issn

1536-4844

pii

4999303

journal_volume

24

pub_type

杂志文章
  • Strategies for detecting colon cancer and dysplasia in patients with inflammatory bowel disease.

    abstract::The risk of colorectal cancer in patients with long-standing ulcerative colitis or colonic Crohn's disease is increased. Patients with long-standing ulcerative colitis are offered enrollment into programs of endoscopic surveillance. Although direct evidence for a protective effect of surveillance against death from co...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0b013e3182802c6a

    authors: Collins PD

    更新日期:2013-03-01 00:00:00

  • A new heterotopic transplant animal model of intestinal fibrosis.

    abstract:BACKGROUND:Severe mucosal tissue damage requiring efficient wound healing is a main feature of inflammatory bowel disease but excessive tissue repair promotes fibrosis. The clinical investigation of fibrosis is confined to the limited amount of biological material available from patients. This makes the establishment o...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e3182a6a0f3

    authors: Hausmann M,Rechsteiner T,Caj M,Benden C,Fried M,Boehler A,Rogler G

    更新日期:2013-10-01 00:00:00

  • Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach.

    abstract::This review examines preclinical and clinical studies relevant to our understanding of how the bidirectional gut-brain axis influences the natural history of inflammatory bowel disease. Preclinical studies provide proof of concept that preexisting behavioral illness, such as depression, results in increased susceptibi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa004

    authors: Collins SM

    更新日期:2020-03-04 00:00:00

  • Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.

    abstract:BACKGROUND:Though vedolizumab has received regulatory approval for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) in adults, there is increasing off-label use in children. AIMS:To describe the experience with vedolizumab in pediatric inflammatory bowel disease (IBD) patients at 3 tertiary IBD center...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000865

    authors: Singh N,Rabizadeh S,Jossen J,Pittman N,Check M,Hashemi G,Phan BL,Hyams JS,Dubinsky MC

    更新日期:2016-09-01 00:00:00

  • Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease.

    abstract:BACKGROUND:The goal of this study was to determine the rate of work disability, unemployment, and sick leave in an unselected inflammatory bowel disease (IBD) cohort and to measure the effect of working status and disability on the patient's health-related quality of life (HRQOL). MATERIALS AND METHODS:All eligible pa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000218762.61217.4a

    authors: Bernklev T,Jahnsen J,Henriksen M,Lygren I,Aadland E,Sauar J,Schulz T,Stray N,Vatn M,Moum B

    更新日期:2006-05-01 00:00:00

  • Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease.

    abstract:Background:Patients requiring optimization of therapy for suboptimal response and/or targeting more robust outcomes may eventually reach high serum levels. Data evaluating the relationship between infliximab concentration and toxicity are limited. The aim of this study was to evaluate the frequency of adverse events (A...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy066

    authors: Greener T,Kabakchiev B,Steinhart AH,Silverberg MS

    更新日期:2018-07-12 00:00:00

  • Outcomes of Endoscopic Therapy for Luminal Strictures in Crohn's Disease.

    abstract:Backgrounds:We sought to describe the outcomes of endoscopic therapy of luminal strictures in patients with Crohn's disease (CD) at a large tertiary referral center. Methods:All patients who had undergone endoscopic dilation of CD strictures between January 1, 1990 and November 30, 2013 were identified. Demographics, ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy049

    authors: Shivashankar R,Edakkanambeth Varayil J,Scott Harmsen W,Faubion WA,Wong Kee Song LM,Bruining DH,Schroeder KW,Kisiel J,Loftus EV Jr,Coelho Prabhu N

    更新日期:2018-06-08 00:00:00

  • Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria.

    abstract::Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are poorly understood disorders affecting the intestinal tract. The current model for disease suggests that genetically susceptible patients develop intolerance to gut microflora, and chronic inflammation develops as a result of environmental i...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000344

    authors: Wang W,Jovel J,Halloran B,Wine E,Patterson J,Ford G,OʼKeefe S,Meng B,Song D,Zhang Y,Tian Z,Wasilenko ST,Rahbari M,Reza S,Mitchell T,Jordan T,Carpenter E,Madsen K,Fedorak R,Dielemann LA,Ka-Shu Wong G,Mason AL

    更新日期:2015-06-01 00:00:00

  • Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings.

    abstract::Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis is the surgical procedure of choice for patients with ulcerative colitis (UC). It is also performed in selected patients with familial adenomatous polyposis (FAP). A significant proportion of patients will develop pouch dysfunction. Flexible pouchosco...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,实务指引,评审

    doi:10.1002/ibd.20874

    authors: McLaughlin SD,Clark SK,Thomas-Gibson S,Tekkis PP,Ciclitira PJ,Nicholls RJ

    更新日期:2009-08-01 00:00:00

  • Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype.

    abstract:BACKGROUND:Blood translocation of bacterial-DNA has been described in patients with Crohn's disease (CD). The host's immune cell types cooperate to respond against bacterial insults. Some antimicrobial peptides are inducible after culture with bacterial products and a linkage has been established between them and NOD2/...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21537

    authors: Gutiérrez A,Holler E,Zapater P,Sempere L,Jover R,Pérez-Mateo M,Schoelmerich J,Such J,Wiest R,Francés R

    更新日期:2011-08-01 00:00:00

  • Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.

    abstract:BACKGROUND:Interestingly, Clostridium difficile infection (CDI) worsens the course of inflammatory bowel disease (IBD); however, there is a paucity of data regarding the treatment of CDI in this group of patients. METHODS:This was a prospective, single-blind trial. Children with flare of IBD and CDI were randomly assi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/MIB.0000000000001249

    authors: Gawronska A,Banasiuk M,Lachowicz D,Pituch H,Albrecht P,Banaszkiewicz A

    更新日期:2017-12-01 00:00:00

  • Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.

    abstract:BACKGROUND:Crohn's disease (CD)-associated dysbiosis could predispose patients to relapse. Gut microbiota composition of patients from the prospective cohort study designed to identify predictive factors of clinical relapse after infliximab discontinuation (STORI Study) was investigated to determine the impact of dysbi...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000036

    authors: Rajca S,Grondin V,Louis E,Vernier-Massouille G,Grimaud JC,Bouhnik Y,Laharie D,Dupas JL,Pillant H,Picon L,Veyrac M,Flamant M,Savoye G,Jian R,Devos M,Paintaud G,Piver E,Allez M,Mary JY,Sokol H,Colombel JF,Seksik P

    更新日期:2014-06-01 00:00:00

  • Colorectal cancer in ulcerative colitis: survival in patients with and without colorectal cancer symptoms.

    abstract::: Patients with ulcerative colitis are at increased risk for colorectal adenocarcinoma compared with the general population. Although surveillance for colorectal malignancy and dysplasia (a premalignant lesion) has been recommended, a benefit in reducing mortality from colorectal cancer via surveillance or prophylacti...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Giardiello FM,Gurbuz AK,Bayless TM,Goodman SN,Yardley JH

    更新日期:1996-04-01 00:00:00

  • Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's disease.

    abstract:BACKGROUND:The etiology of ulcerative colitis (UC) and Crohn's disease (CD) involves both genetic and environmental components. Multiple UC and CD susceptibility genes have been identified through genome-wide association studies and subsequent meta-analyses. These studies have also highlighted the presence of genes com...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1097/MIB.0b013e3182810041

    authors: Doecke JD,Simms LA,Zhao ZZ,Huang N,Hanigan K,Krishnaprasad K,Roberts RL,Andrews JM,Mahy G,Bampton P,Lewindon P,Florin T,Lawrance IC,Gearry RB,Montgomery GW,Radford-Smith GL

    更新日期:2013-02-01 00:00:00

  • Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

    abstract:BACKGROUND:Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to determine how an obje...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000376

    authors: Huang VW,Prosser C,Kroeker KI,Wang H,Shalapay C,Dhami N,Fedorak DK,Halloran B,Dieleman LA,Goodman KJ,Fedorak RN

    更新日期:2015-06-01 00:00:00

  • Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

    abstract:BACKGROUND:A notable proportion of patients with inflammatory bowel disease (IBD) are switched from infliximab (IFX) to adalimumab (ADL). We investigated if immunogenicity of IFX influenced immunogenicity and clinical outcomes of later ADL therapy. METHODS:Single-center cohort study including all patients with IBD ass...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/MIB.0000000000000138

    authors: Frederiksen MT,Ainsworth MA,Brynskov J,Thomsen OO,Bendtzen K,Steenholdt C

    更新日期:2014-10-01 00:00:00

  • Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

    abstract::Our aims were to assess the impact on health-related quality of life (HRQOL) of a controlled ileal release (CIR) formulation of budesonide in active Crohn's disease (CD) and further define the role of HRQOL, using the Inflammatory Bowel Disease Questionnaire (IBDQ), in assessing outcome in CD. A randomized trial was c...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00054725-200008000-00004

    authors: Irvine EJ,Greenberg GR,Feagan BG,Martin F,Sutherland LR,Thomson AB,Nilsson LG,Persson T

    更新日期:2000-08-01 00:00:00

  • Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.

    abstract:Background:Both muscle-related complaints and elevated serum creatine kinase (CK) levels have been reported in patients with inflammatory bowel disease (IBD) treated with infliximab (IFX), mainly as case reports. The aim of this study was to investigate the effect of IFX therapy on serum CK levels in a cohort of Greek ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy088

    authors: Theodoraki E,Orfanoudaki E,Foteinogiannopoulou K,Koutroubakis IE

    更新日期:2018-05-18 00:00:00

  • Critical appraisal of the current practice in murine TNBS-induced colitis.

    abstract::There is no standard practice in the induction of colitis by 2,4,6-trinitrobenzene sulfonic acid. In this review the current practice in 2,4,6-trinitrobenzene sulfonic acid colitis is studied using 20 recently published articles. We compare the different protocols, discuss the mechanism of disease and give recommendat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/01.mib.0000227817.54969.5e

    authors: te Velde AA,Verstege MI,Hommes DW

    更新日期:2006-10-01 00:00:00

  • Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.

    abstract:BACKGROUND:Mesalazine preparations are widely used to treat mild to moderately severe ulcerative colitis (UC). We compared once-daily administration of oral mesalazine in patients with quiescent UC with the established 3-times-daily prescription, assessing the efficacy and safety of each method in maintaining remission...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/MIB.0b013e318286fa3d

    authors: Watanabe M,Hanai H,Nishino H,Yokoyama T,Terada T,Suzuki Y

    更新日期:2013-07-01 00:00:00

  • Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI Disorders.

    abstract:BACKGROUND:Clinical observations or animal studies implicate enteric glial cells in motility disorders, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal (GI) infections, postoperative ileus, and slow transit constipation. Mechanisms underlying glial responses to inflammation in human GI tract are ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000854

    authors: Liñán-Rico A,Turco F,Ochoa-Cortes F,Harzman A,Needleman BJ,Arsenescu R,Abdel-Rasoul M,Fadda P,Grants I,Whitaker E,Cuomo R,Christofi FL

    更新日期:2016-08-01 00:00:00

  • Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?

    abstract:BACKGROUND:The consistency of endoscopic and histologic findings in patients with ulcerative colitis (UC) has not been elucidated. Choice of assessment may affect study outcomes. METHODS:Post hoc analyses were performed using data from 2 randomized, controlled multicenter trials: (1) SAG-26, mesalazine granules for in...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000437044.43961.00

    authors: Wolff S,Terheggen G,Mueller R,Greinwald R,Franklin J,Kruis W

    更新日期:2013-11-01 00:00:00

  • Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis.

    abstract:BACKGROUND:Guidelines mandate screening for latent tuberculosis infection (LTBI) prior to anti-tumor necrosis factor (anti-TNF) therapy in patients with inflammatory bowel disease (IBD). However, many are already on immunosuppressive therapy (IST) that may affect the precision of the Tuberculin skin test (TST). Our aim...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1002/ibd.22901

    authors: Shahidi N,Fu YT,Qian H,Bressler B

    更新日期:2012-11-01 00:00:00

  • Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery.

    abstract:BACKGROUND AND AIMS:Poor sleep quality in Crohn's disease (CD) is associated with histologic activity and clinical relapse. We sought to characterize sleep dysfunction and determine the effect of poor sleep quality on risk for hospitalization and surgery. METHODS:Clinical data were collected for CD subjects including ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz258

    authors: Sofia MA,Lipowska AM,Zmeter N,Perez E,Kavitt R,Rubin DT

    更新日期:2020-07-17 00:00:00

  • Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up.

    abstract:BACKGROUND:This study compared the efficacy of an elemental formula (EF) to a polymeric formula (PF) in inducing remission for pediatric Crohn's disease (CD). METHODS:Newly diagnosed CD children were randomized to EF or PF for 6 weeks. Change in the Pediatric Crohn's Disease Activity Index (PCDAI), fecal calprotectin,...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21690

    authors: Grogan JL,Casson DH,Terry A,Burdge GC,El-Matary W,Dalzell AM

    更新日期:2012-02-01 00:00:00

  • Infliximab therapy in pediatric Crohn's pouchitis.

    abstract:OBJECTIVE:We describe the prolonged clinical benefit of murine chimeric antitumor necrosis factor (TNF)-alpha monoclonal antibody, infliximab, on pediatric patients with Crohn's disease and ileal pouch anal anastomosis (IPAA). METHODS:A retrospective review of patients originally diagnosed with ulcerative colitis, sta...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200407000-00013

    authors: Kooros K,Katz AJ

    更新日期:2004-07-01 00:00:00

  • Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset.

    abstract:BACKGROUND:As the American population is aging, the number of older people with inflammatory bowel disease is increasing. We used clinical data from the Sinai-Helmsley Alliance for Research Excellence (SHARE), a prospective cohort, to examine disease and treatment differences in older adults. METHODS:We performed a cr...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001115

    authors: Kochar B,Long MD,Galanko J,Raffals LE,Ananthakrishnan A,Sandler RS

    更新日期:2017-07-01 00:00:00

  • The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.

    abstract:Background:Clinical trials investigating the use of cannabinoid drugs for the treatment of intestinal inflammation are anticipated secondary to preclinical literature demonstrating efficacy in reducing inflammation. Methods:We systematically reviewed publications on the benefit of drugs targeting the endo-cannabinoid ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izy014

    authors: Couch DG,Maudslay H,Doleman B,Lund JN,O'Sullivan SE

    更新日期:2018-03-19 00:00:00

  • Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.

    abstract:BACKGROUND:The clinical utility of cellular therapies is being investigated in a broad range of therapeutic areas. This phase 1 study represents the first exploration of PDA001, a preparation of cells cultured from human placental tissue, in subjects with Crohn's disease. METHODS:Twelve subjects with active, moderate-...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0b013e31827f27df

    authors: Mayer L,Pandak WM,Melmed GY,Hanauer SB,Johnson K,Payne D,Faleck H,Hariri RJ,Fischkoff SA

    更新日期:2013-03-01 00:00:00

  • Healing of intestinal inflammation by IL-22.

    abstract::An interleukin (IL)-10 family cytokine, IL-22 is characterized by several unique biological properties, including 1) the target restricted to innate cells; 2) the distinct expression pattern between large and small intestines; 3) alteration of the cellular source depending on several factors; 4) the dual abilities to ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.22929

    authors: Mizoguchi A

    更新日期:2012-09-01 00:00:00